Zomedica Pharmaceuticals logo

ZOM - Zomedica Pharmaceuticals Share Price

C$0.285 0.0  0.0%

Last Trade - 05/02/20

Sector
Healthcare
Size
Micro Cap
Market Cap £30.5m
Enterprise Value £30.5m
Revenue £n/a
Position in Universe th / 2657
Bullish
Bearish
Unlock ZOM Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Financial Summary
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Zomedica Pharmaceuticals Corp revenues was not reported. Net loss decreased 79% to $2.5M. Lower net loss reflects Research and development decrease of 95% to $401K (expense), Labor & Related Expenses in SGA decrease of 74% to $751K (expense), Professional fees decrease of 61% to $291K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.12 to -$0.02.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ZOM Revenue Unlock ZOM Revenue

Net Income

ZOM Net Income Unlock ZOM Revenue

Normalised EPS

ZOM Normalised EPS Unlock ZOM Revenue

PE Ratio Range

ZOM PE Ratio Range Unlock ZOM Revenue

Dividend Yield Range

ZOM Dividend Yield Range Unlock ZOM Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ZOM EPS Forecasts Unlock ZOM Revenue
Profile Summary

Zomedica Pharmaceuticals Corp is a development stage veterinary diagnostic and pharmaceutical company. The Company is engaged in developing products for companion animals, such as canine, feline, and equine by focusing on needs of clinical veterinarians. It is focused on developing three diagnostic platforms, a Bulk Acoustic Wave sensor-based veterinary point-of-care diagnostic platform for performing immunodiagnostic testing, a Raman spectroscopy-based point-of-care diagnostic platform for the detection of pathogens, and liquid biopsy assays for the detection of cancer, along with related consumables. The Company’s TRUFORMA product candidate is an investigational device being developed as a point-of-care biosensor platform. ZM-020 is its diagnostic platform being developed to screen for a range of pathogens in companion animal feces, urine, respiratory, and dermatological samples. It is developing ZM-017 as a canine cancer liquid biopsy platform.

Directors
Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated January 7, 2013
Public Since October 28, 2013
No. of Shareholders: n/a
No. of Employees: 28
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange TSX Venture Exchange
Shares in Issue 166,538,233
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ZOM Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ZOM
Upcoming Events for ZOM
Frequently Asked Questions for Zomedica Pharmaceuticals
What is the Zomedica Pharmaceuticals share price?

As of 05/02/20, shares in Zomedica Pharmaceuticals are trading at C$0.285, giving the company a market capitalisation of £30.5m. This share price information is delayed by 15 minutes.

How has the Zomedica Pharmaceuticals share price performed this year?

Shares in Zomedica Pharmaceuticals are currently trading at C$0.285 and the price has moved by -83.24% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Zomedica Pharmaceuticals price has moved by -82.15% over the past year.

What are the analyst and broker recommendations for Zomedica Pharmaceuticals?

There are no analysts currently covering Zomedica Pharmaceuticals.

When will Zomedica Pharmaceuticals next release its financial results?

Zomedica Pharmaceuticals is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Zomedica Pharmaceuticals dividend yield?

Zomedica Pharmaceuticals does not currently pay a dividend.

Does Zomedica Pharmaceuticals pay a dividend?

Zomedica Pharmaceuticals does not currently pay a dividend.

When does Zomedica Pharmaceuticals next pay dividends?

Zomedica Pharmaceuticals does not currently pay a dividend.

How do I buy Zomedica Pharmaceuticals shares?

To buy shares in Zomedica Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Zomedica Pharmaceuticals?

Shares in Zomedica Pharmaceuticals are currently trading at C$0.285, giving the company a market capitalisation of £30.5m.

Where are Zomedica Pharmaceuticals shares listed? Where are Zomedica Pharmaceuticals shares listed?

Here are the trading details for Zomedica Pharmaceuticals:

Country of listing: Canada
Exchange: CVE
Ticker Symbol: ZOM
What kind of share is Zomedica Pharmaceuticals?

We were not able to load our ranking data for Zomedica Pharmaceuticals

Is there a Zomedica Pharmaceuticals share price forecast 2020?

We were not able to load any forecast data for Zomedica Pharmaceuticals.

How can I tell whether the Zomedica Pharmaceuticals share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Zomedica Pharmaceuticals. Over the past six months, the relative strength of its shares against the market has been 12.1%. At the current price of C$0.285, shares in Zomedica Pharmaceuticals are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Zomedica Pharmaceuticals PE Ratio?

We were not able to find PE ratio data for Zomedica Pharmaceuticals.

Who are the key directors of Zomedica Pharmaceuticals?

Zomedica Pharmaceuticals's management team is headed by:

Stephanie Morley - PRE
William MacArthur - EDR
Angy Guerrant - OTH
Bruk Herbst - OTH
Shameze Rampertab - CEO
Angie Moricz - OTH
Andrea Eberle - OTH
Jane Eagleson - IND
Thomas Robitaille - IND
Jeffrey Rowe - CHM
Rodney Williams - IND
Johnny Powers - IND
Who are the major shareholders of Zomedica Pharmaceuticals?

Here are the top five shareholders of Zomedica Pharmaceuticals based on the size of their shareholding:

Solensky (Gerald Jr) Individual Investor
Percentage owned: 23.15% (38.5m shares)
Rowe Family GST Trust Corporation
Percentage owned: 6.68% (11.1m shares)
Equidebt, L.L.C. Corporation
Percentage owned: 5.6% (9.32m shares)
Sabby Management, LLC Investment Advisor/Hedge Fund
Percentage owned: 5% (8.33m shares)
Armistice Capital LLC Hedge Fund
Percentage owned: 4.06% (6.77m shares)
Similar to ZOM
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.